New York Oncology Hematology | Albany, NY

Research site

(Unclaimed)

Location

400 Patroon Creek Boulevard, Albany, New York, United States of America

Site insights

Top conditions

Top treatments

Niraparib

Daratumumab

Bevacizumab

Prednisone Versus Abiraterone Acetate

Lenalidomide

Prednisone

Abiraterone Acetate

Pembrolizumab

relatlimab+nivolumab

INCB001158

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 38 total trials

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus...

Active, not recruiting

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Drug: Capecitabine

Drug: Tislelizumab

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenali...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Daratumumab

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells in the bone marrow.The main aim of this study is to learn how well the Immune Globulin Infusion (hum...

Enrolling

Secondary Immunodeficiency

Multiple Myeloma

Biological: IGI, 10%

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (QUEST)

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting

Prostatic Neoplasms, Castration-Resistant

Drug: Niraparib 200 mg

Drug: Cetrelimab 480 mg

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting

Metastatic Castration-sensitive Prostate Cancer

Drug: Niraparib

Drug: Prednisone

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting

Castration-Resistant Prostatic Cancer

Drug: Prednisone

Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-em...

Enrolling

Recurrent Ovarian Cancer

Folate Receptor-Alpha Positive

Drug: Lubricating Eye Drops

Drug: Prednisolone acetate ophthalmic suspension 1% eye drops

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting

Smoldering Multiple Myeloma

Drug: Daratumumab SC: daratumumab + rHuPH20

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also kn...

Enrolling

Melanoma

Drug: fianlimab

Drug: cemiplimab

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclis...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Teclistamab

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive an...

Enrolling

Breast Cancer

Biological: Placebo

Biological: GLSI-100

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment (LUNA 4)

This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP...

Enrolling

Immune Thrombocytopenia

Drug: rilzabrutinib

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advance...

Enrolling

Urothelial Carcinoma

Urothelial Cancer

Biological: Enfortumab Vedotin

Biological: PF-08634404

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treat...

Enrolling

Carcinoma, Non-Small-Cell Lung (NSCLC)

Lung Cancer

Biological: Pembrolizumab

Biological: PF-08634404